Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
July 10th, 2007
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with arimoclomol in ALS volunteers. While the clinical trial was not placebo-controlled, arimoclomol at a 100 mg dose three times daily appeared to be safe and well-tolerated throughout the six-month period. Further, the rate of decline of several key disease symptom indicators, including the Revised ALS Functional Rating Scale (ALSFRS-R), which measures overall functional capacity, and vital capacity, which measures breathing ability, in the...
Source: Drug Law Weekly (2007-07-10)
|
